Abstract:Objective: To explore the relationship between serum long-stranded non-coding RNA myoprotein antisense RNA 1 (LncRNA-MSC-AS1) level and clinicopathological features and prognosis in patients with ovarian cancer (OC). Methods: A total of 106 OC patients admitted to our hospital from November 2016 to November 2018 were taken as the OC group, and 106 normal healthy subjects were taken as the control group. The expression level of LncRNA-MSC-AS1 in serum was detected by quantitative real-time PCR (qRT-PCR); Kaplan-Meier survival curve was used to analyze the relationship between LncRNA-MSC-AS1 expression level and 3-year survival in OC patients; Cox regression analysis of risk factors affecting adverse prognosis of OC patients at 3 years after surgery. Results: The expression of LncRNA-MSC-AS1 in OC group (0.75±0.08) was lower than that in control group (1.01±0.11) (t=19.681, P<0.05); the expression level of LncRNA-MSC-AS1 in OC patients was correlated with TNM stage, lymph node metastasis, tumor diameter, and CA125 (P<0.05); Kaplan-Meier survival curve analysis showed that the 3-year survival rate of the high expression group of LncRNA-MSC-AS1 was 71.15% (37/52), which was significantly higher than that of the low expression group (37.04% (20/54). (Log rank χ2=12.404, P<0.001); COX regression analysis showed that TNM stage, tumor diameter, low expression of CA125 and LncRNA-MSC-AS1 were risk factors for poor prognosis of OC patients at 3 years after operation (P<0.05). Conclusion: LncRNA-MSC-AS1 is under-expressed in OC patients, which is related to the clinicopathological characteristics and prognosis of OC patients, and is expected to be a potential biomarker for OC prognosis assessment.
李翠娥, 何晓丽, 何洁丽, 陈贝, 王燕, 李晶. 卵巢癌患者血清LncRNA-MSC-AS1水平与临床病理特征及预后的关系[J]. 河北医学, 2023, 29(5): 767-772.
LI Cui'e, HE Xiaoli, HE Jieli, et al. Relationship between Serum LncRNA-MSC-AS1 Level and Clinicopathological Features and Prognosis in Patients with Ovarian Cancer. HeBei Med, 2023, 29(5): 767-772.